Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2017

01-12-2017 | Preclinical study

African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages

Authors: Cletus A. Arciero, Jing Yang, Limin Peng, Kevin C. Ward, Ruth O’Regan, Aysegul A. Sahin, Xiaoxian Li

Published in: Breast Cancer Research and Treatment | Issue 3/2017

Login to get access

Abstract

Purpose

Racial disparity of breast cancer in each subtype and substage is not clear.

Methods

We reviewed 156,938 patients with breast cancer from 2010 to 2012 from the National Cancer Institute Surveillance, Epidemiology, and End Results database. Breast cancer was subtyped by hormone receptor (HR) and human epidermal growth factor 2 (HER2) status as HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2−.

Results

African American (AA) patients had worse overall survival (OS) and breast cancer cause-specific survival (BCSS) in HR+/HER2− stages III and IV breast cancer and HR−/HER2+ stage IV cancer; they had worse OS but not BCSS in HR+ /HER2− stage II cancer and HR−/HER2− stage II cancer.

Conclusion

AA patients with breast cancer had worse survival in certain subtype and stage, especially in ER+ breast cancer.
Literature
1.
Whitman S, Orsi J, Hurlbert M (2012) The racial disparity in breast cancer mortality in the 25 largest cities in the United States. Cancer Epidemiol 36:e147–e151CrossRefPubMed
2.
Newman LA, Griffith KA, Jatoi I et al (2006) Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24:1342–1349CrossRefPubMed
3.
O’Brien KM, Cole SR, Tse CK et al (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100–6110CrossRefPubMedPubMedCentral
4.
Menashe I, Anderson WF, Jatoi I et al (2009) Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst 101:993–1000CrossRefPubMedPubMedCentral
5.
Schinkel JK, Zahm SH, Jatoi I et al (2014) Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data. Cancer Causes Control 25:959–968CrossRefPubMed
6.
Adams SA, Butler WM, Fulton J et al (2012) Racial disparities in breast cancer mortality in a multiethnic cohort in the Southeast. Cancer 118:2693–2699CrossRefPubMed
7.
8.
Warner ET, Tamimi RM, Hughes ME et al (2015) Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol 33:2254–2261CrossRefPubMedPubMedCentral
9.
Iqbal J, Ginsburg O, Rochon PA et al (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313:165–173CrossRefPubMed
10.
Mortel M, Rauscher GH, Murphy AM et al (2015) Racial and ethnic disparity in symptomatic breast cancer awareness despite a recent screen: the role of tumor biology and mammography facility characteristics. Cancer Epidemiol Biomark Prev 24:1599–1606CrossRef
11.
Sparano JA, Wang M, Zhao F et al (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104:406–414CrossRefPubMedPubMedCentral
12.
Roseland ME, Pressler ME, Lamerato LE et al (2015) Racial differences in breast cancer survival in a large urban integrated health system. Cancer 121:3668–3675CrossRefPubMed
13.
Nurgalieva ZZ, Franzini L, Morgan R et al (2013) Surveillance mammography use after treatment of primary breast cancer and racial disparities in survival. Med Oncol 30:691CrossRefPubMed
14.
Dave B, Gonzalez DD, Liu ZB et al (2017) Role of RPL39 in metaplastic breast cancer. J Natl Cancer Inst 109
15.
Krishnamurti U, Wetherilt CS, Yang J et al (2017) Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Hum Pathol 64:7–12CrossRefPubMed
16.
Li X, Oprea-Ilies GM, Krishnamurti U (2017) New developments in breast cancer and their impact on daily practice in pathology. Arch Pathol Lab Med 141:490–498CrossRefPubMed
17.
Li X, Wei B, Sonmez C et al (2017) High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma. Hum Pathol
18.
Li X, Wetherilt CS, Krishnamurti U et al (2016) Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer. Am J Clin Pathol 146:496–502CrossRefPubMed
19.
Li X, Yang J, Krishnamurti U et al (2017) Hormone receptor-positive breast cancer has a worse prognosis in male than in female patients. Clin Breast Cancer 17:356–366CrossRefPubMed
20.
Li X, Yang J, Peng L et al (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161:279–287CrossRefPubMed
21.
Li XB, Krishnamurti U, Bhattarai S et al (2016) Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol 145:871–878CrossRefPubMed
22.
Ogden A, Garlapati C, Li XB et al (2017) Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer. Sci Rep 7:42289CrossRefPubMedPubMedCentral
23.
Pannu V, Mittal K, Cantuaria G et al (2015) Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers. Oncotarget 6:10487–10497CrossRefPubMedPubMedCentral
24.
Wright N, Rida P, Krishnamurti U et al (2017) Targeted drugs and diagnostic assays: companions in the race to combat ethnic disparity. Front Biosci (Landmark Ed) 22:193–211CrossRef
25.
Wright N, Xia J, Cantuaria G et al (2017) Distinctions in breast tumor recurrence patterns post-therapy among racially distinct populations. PLoS ONE 12:e0170095CrossRefPubMedPubMedCentral
26.
Zelnak AB, Nikolinakos P, Srinivasiah J et al (2015) High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy. Clin Breast Cancer 15:31–36CrossRefPubMed
27.
Lund MJ, Trivers KF, Porter PL et al (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370CrossRefPubMed
28.
Dawood S, Broglio K, Kau SW et al (2009) Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27:220–226CrossRefPubMedPubMedCentral
29.
Chu KC, Lamar CA, Freeman HP (2003) Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer 97:2853–2860CrossRefPubMed
30.
Ma H, Lu Y, Malone KE et al (2013) Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer 13:1–11CrossRef
31.
Gleason MX, Mdzinarishvili T, Sherman S (2012) Breast cancer incidence in black and white women stratified by estrogen and progesterone receptor statuses. PLoS ONE 7:e49359CrossRefPubMedPubMedCentral
32.
Wright JL, Reis IM, Zhao W et al (2012) Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy. Breast 21:276–283CrossRefPubMed
33.
Vaz-Luis I, Lin NU, Keating NL et al (2015) Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat 151:697–707CrossRefPubMed
34.
Tichy JR, Deal AM, Anders CK et al (2015) Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat 150:667–674CrossRefPubMedPubMedCentral
35.
EBCTCG (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341–1352CrossRef
36.
EBCTCG (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784CrossRef
37.
Fisher B, Jeong J-H, Bryant J et al (2004) Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National surgical adjuvant breast and bowel project randomised clinical trials. Lancet 364:858–868CrossRefPubMed
38.
Friese CR, Pini TM, Li Y et al (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138:931–939CrossRefPubMedPubMedCentral
39.
Neugut AI, Subar M, Wilde ET et al (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534–2542CrossRefPubMedPubMedCentral
40.
Roberts MC, Wheeler SB, Reeder-Hayes K (2015) Racial/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. Am J of Public Health 105:e4–e15CrossRef
41.
Ma H, Lu Y, Marchbanks PA et al (2013) Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Breast Cancer Res 15:1–12CrossRef
42.
Reding KW, Chen C, Lowe K et al (2012) Estrogen-related genes and their contribution to racial differences in breast cancer risk. Cancer Causes Control 23:671–681CrossRefPubMedPubMedCentral
Metadata
Title
African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages
Authors
Cletus A. Arciero
Jing Yang
Limin Peng
Kevin C. Ward
Ruth O’Regan
Aysegul A. Sahin
Xiaoxian Li
Publication date
01-12-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4484-1

Other articles of this Issue 3/2017

Breast Cancer Research and Treatment 3/2017 Go to the issue

Preclinical study

Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines

Epidemiology

Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography

Preclinical study

BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells

Preclinical study

Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma

Preclinical study

Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis

Epidemiology

Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits